journal article·2018-07-04Open access

Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells

Raana Farajzadeh, Younes Pilehvar-Soltanahmadi, Mehdi Dadashpour, Shahrzad Javidfar, Javid Lotfi-Attari, Hadi Sadeghzadeh, Vahid Shafiei-Irannejad, Nosratollah Zarghami

Abstract

The study was aimed at investigating the synergistic inhibitory effect of unique combinational regimen of nanocapsulated Metformin (Met) and Curcumin (Cur) against T47D breast cancer cells. For this purpose, Met and Cur were co-encapsulated in PEGylated PLGA nanoparticles (NPs) and evaluated for their therapeutic efficacy. The morphology and dynamic light scattering (DLS) analyses were carried out to optimize the nanoformulations. Drug release study was performed using dialysis method and then the cytotoxic and inhibitory effect of individual and combined drugs on expression level of hTERT in T47D breast cell line were evaluated using MTT assay and qPCR, respectively. The results showed that free drugs and formulations exhibited a dose-dependent cytotoxicity against T47D cells and especially, Met-Cur-PLGA/PEG NPs had more synergistic antiproliferative effect and significantly arrested the growth of cancer cells than the other groups (p < .05). Real-time PCR results revealed that Cur, Met and combination of Met-Cur in free and encapsulated forms inhibited hTERT gene expression. It was found that Met-Cur-PLGA/PEG NPs in relative to free combination could further decline hTERT expression in all concentration (p < .05). Taken together, our study demonstrated that Met-Cur-PLGA/PEG NPs based combinational therapy holds promising potential towards the treatment of breast cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Retinoids in leukemia and cellular processes · Curcumin's Biomedical Applications · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences

Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Funding

Tabriz University of Medical Sciences

References (36)

Show source-provided references
1. 10.3109/21691401.2015.100851010.3109/21691401.2015.1008510 ↗
2. 10.3109/21691401.2015.102963310.3109/21691401.2015.1029633 ↗
3. 10.7314/APJCP.2014.15.17.711310.7314/APJCP.2014.15.17.7113 ↗
4. 10.3109/21691401.2014.98280310.3109/21691401.2014.982803 ↗
5. 10.4137/BCBCR.S673410.4137/BCBCR.S6734 ↗
6. 10.1016/j.gene.2012.01.09510.1016/j.gene.2012.01.095 ↗
7. 10.3748/wjg.v20.i21.661510.3748/wjg.v20.i21.6615 ↗
8. Javan-Maasomi Z, Pilehvar-Soltanahmadi Y, Dadashpour M, et al. Synergistic anticancer effects of silibinin and chrysin in T47D breast cancer cells. Asian Pac J Cancer Prev. 2017;18:1283–1287.
9. 10.1016/j.biomaterials.2014.04.03410.1016/j.biomaterials.2014.04.034 ↗
10. 10.3892/or.2013.231010.3892/or.2013.2310 ↗
11. 10.18632/oncotarget.624310.18632/oncotarget.6243 ↗
12. 10.1016/j.ijpharm.2013.06.01710.1016/j.ijpharm.2013.06.017 ↗
13. 10.2174/092986732366616042511370510.2174/0929867323666160425113705 ↗
14. 10.1016/j.biomaterials.2013.12.09010.1016/j.biomaterials.2013.12.090 ↗
15. 10.1007/s12032-011-9846-710.1007/s12032-011-9846-7 ↗
16. Kazemi-Lomedasht F, Rami A, Zarghami N. Comparison of inhibitory effect of curcumin nanoparticles and free curcumin in human telomerase reverse transcriptase gene expression in breast cancer. Adv Pharm Bull. 2013;3:127–130.
17. 10.1016/j.jconrel.2016.11.00510.1016/j.jconrel.2016.11.005 ↗
18. 10.7314/APJCP.2014.15.20.893110.7314/APJCP.2014.15.20.8931 ↗
19. 10.1080/21691401.2016.127692210.1080/21691401.2016.1276922 ↗
20. 10.2174/187152061766617021311575610.2174/1871520617666170213115756 ↗
21. 10.3109/21691401.2015.112961510.3109/21691401.2015.1129615 ↗
22. 10.7314/APJCP.2014.15.2.51710.7314/APJCP.2014.15.2.517 ↗
23. 10.1186/s12951-015-0086-410.1186/s12951-015-0086-4 ↗
24. 10.1007/s00396-009-2131-z10.1007/s00396-009-2131-z ↗
25. Athira GK, Jyothi AN. Preparation and characterization of curcumin loaded cassava starch nanoparticles with improved cellular absorption. Int J Pharm Pharm Sci. 2014;6:171–176.
26. 10.1016/j.vibspec.2012.05.00210.1016/j.vibspec.2012.05.002 ↗
27. 10.3109/1061186X.2013.83746910.3109/1061186X.2013.837469 ↗
28. 10.1158/0008-5472.CAN-09-194710.1158/0008-5472.CAN-09-1947 ↗
29. 10.7314/APJCP.2013.14.6.344910.7314/APJCP.2013.14.6.3449 ↗
30. 10.1007/s13277-013-0757-410.1007/s13277-013-0757-4 ↗
31. 10.1016/j.canlet.2009.08.02610.1016/j.canlet.2009.08.026 ↗
32. 10.2174/187152061666616081512453710.2174/1871520616666160815124537 ↗
33. 10.1016/j.ijpharm.2016.05.03910.1016/j.ijpharm.2016.05.039 ↗
34. 10.2174/0929867311320666013510.2174/09298673113206660135 ↗
35. 10.2174/092986732366616042511370510.2174/0929867323666160425113705 ↗
36. 10.1158/1535-7163.MCT-06-003310.1158/1535-7163.MCT-06-0033 ↗